Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tadaaki Yamada MD, PhD"'
Autor:
Yuri Ogura MD, Masahiro Iwasaku MD, PhD, Mami Ishida MD, PhD, Yuki Katayama MD, PhD, Naoya Nishioka MD, PhD, Kenji Morimoto MD, PhD, Chie Yamamoto MD, Shinsaku Tokuda MD, PhD, Yoshiko Kaneko MD, PhD, Tadaaki Yamada MD, PhD, Hideya Yamazaki MD, PhD, Masayoshi Inoue MD, PhD, Hiroshi Ikai MD, PhD, Koichi Takayama MD, PhD
Publikováno v:
Cancer Control, Vol 31 (2024)
Introduction This study aimed to describe the course of patients with lung cancer from treatment initiation to end-of-life. Methods This retrospective cohort study used Claims Data from the National Health Insurance and Advanced Elderly Medical Servi
Externí odkaz:
https://doaj.org/article/0ef4cb67c5834d4c908892435bb4fc2d
Autor:
Yuki Katayama, MD, PhD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, PhD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100644- (2024)
Introduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitor
Externí odkaz:
https://doaj.org/article/3964141379334812bbe15faf7291e902
Autor:
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100525- (2023)
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treat
Externí odkaz:
https://doaj.org/article/27b3e58854a34814b01a239b63d7e6ea
Autor:
Yuki Katayama, MD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Akihiro Yoshimura, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100494- (2023)
Introduction: Lung adenocarcinoma with negative TTF-1 expression is believed to be a poor prognostic factor for certain systemic treatments. Nevertheless, the impact of TTF-1 expression on combined chemoimmunotherapy remains unclear. We aimed to inve
Externí odkaz:
https://doaj.org/article/f5a29b79c158468da31bfa4f00a93ada
Autor:
Masaki Ishida, MD, Kenji Morimoto, MD, PhD, Tadaaki Yamada, MD, PhD, Takayuki Takeda, MD, PhD, Shinsuke Shiotsu, MD, PhD, Koji Date, MD, Taishi Harada, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Yoshizumi Takemura, MD, PhD, Takahiro Yamada, MD, PhD, Hibiki Kanda, MD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100493- (2023)
Introduction: In recent years, programmed cell death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy was found to have favorable clinical outcomes in patients with extensive-stage SCLC (ES-SCLC). The usefulness of early tumor shrinkag
Externí odkaz:
https://doaj.org/article/8ad42c2ad9154398a211e05aa540b2ca
Autor:
Kenji Morimoto, MD, PhD, Ryo Sawada, MD, Tadaaki Yamada, MD, PhD, Koichi Azuma, MD, PhD, Kentaro Ito, MD, Yasuhiro Goto, MD, PhD, Hideharu Kimura, MD, PhD, Taishi Harada, MD, Shinsuke Shiotsu, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Takayuki Takeda, MD, PhD, Osamu Hiranuma, MD, Isao Hasegawa, MD, PhD, Yoshie Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100388- (2022)
Introduction: The use of immune checkpoint inhibitors (ICIs) with chemotherapy has increased the survival of patients with advanced NSCLC. Nevertheless, the efficacy of ICI treatment for NSCLC with EGFR mutations is limited. Previous studies have not
Externí odkaz:
https://doaj.org/article/1e1fc663904a4f5abcb4031e0440a538
Autor:
Kenji Morimoto, MD, PhD, Tadaaki Yamada, MD, PhD, Takayuki Takeda, MD, PhD, Shinsuke Shiotsu, MD, Koji Date, MD, Taishi Harada, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Hibiki Kanda, MD, Takayuki Nakano, PhD, Yoshie Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100353- (2022)
Introduction: To date, the efficacy and safety of programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy for patients with extensive-stage SCLC (ES-SCLC), with real-world evidence, stratified on the basis of age and performa
Externí odkaz:
https://doaj.org/article/c7edde061feb4e788e7779457729f41b